Zolpidem
| Evidence Level: L1 | Predicted Indications: 3 |
Table of Contents
- Zolpidem
- Zolpidem: From Unmarketed Status in India to Insomnia (Sleep Disorder of Initiating and Maintaining Sleep)
Zolpidem: From Unmarketed Status in India to Insomnia (Sleep Disorder of Initiating and Maintaining Sleep)
One-Sentence Summary
Zolpidem is not currently registered or marketed in India, so no local approved indication exists in the regulatory record. The TxGNN model predicts it is effective for Sleep Disorder, Initiating and Maintaining Sleep (Insomnia) — which is in fact Zolpidem’s well-established, globally recognized indication — supported by 21 publications, including multiple Phase 3 randomized controlled trials and network meta-analyses, though no clinical trials are currently indexed in this evidence pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no India market license on record. (Well-established global indication: insomnia, non-benzodiazepine hypnotic) |
| Predicted New Indication | Sleep disorder, initiating and maintaining sleep (Insomnia) |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L1 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack (original_moa: [Data Gap]). Based on well-established pharmacological knowledge, Zolpidem is a non-benzodiazepine hypnotic (“Z-drug”) that acts as a selective agonist at the α1 subunit of the GABA-A receptor. This mechanism produces sedative-hypnotic effects with a more selective receptor profile than traditional benzodiazepines, and its efficacy for insomnia has been documented internationally for over three decades.
Notably, this case differs from a typical “repurposing” scenario: the predicted indication (insomnia) is not a novel disease area for Zolpidem but its core, already-known therapeutic use. The evidence pack shows Zolpidem is not currently registered in India (0 licenses, market status “Not marketed”), so the practical significance of this TxGNN prediction is less about discovering a new mechanism and more about confirming strong, pre-existing evidence for a potential first-time market introduction of Zolpidem in India.
The literature evidence reflects this maturity: Zolpidem appears repeatedly as the active comparator in modern Phase 3 trials of newer hypnotics (lemborexant, daridorexant), and in multiple meta-analyses and network meta-analyses evaluating pharmacological treatments for insomnia — indicating an extensive, decades-deep evidence base rather than early-stage or purely computational signal.
Clinical Trial Evidence
Currently no related clinical trials registered (the clinical_trials and ictrp_trials fields for this indication are empty; clinical trial evidence for Zolpidem is instead embedded within the literature listed below).
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 31880796 | 2019 | Phase 3 RCT | JAMA Network Open | Direct comparison of lemborexant vs. placebo vs. zolpidem tartrate ER in older adults with insomnia disorder |
| 34688027 | 2021 | Meta-analysis of RCTs | Sleep Medicine | Confirms efficacy and safety of zolpidem for insomnia treatment over one month |
| 35843245 | 2022 | Network meta-analysis | Lancet | Comparative effectiveness of pharmacological interventions (incl. zolpidem) for acute and long-term insomnia management |
| 34121443 | 2021 | Network meta-analysis | J Manag Care Spec Pharm | Comparative efficacy and safety of lemborexant and other insomnia treatments, including zolpidem |
| 36472134 | 2023 | Comparative RCT-derived analysis | J Clin Sleep Med | Polysomnography-based comparison of lemborexant vs. zolpidem ER 6.25mg across insomnia subtypes |
| 37477771 | 2023 | Post-hoc RCT analysis | CNS Drugs | Effects of daridorexant vs. zolpidem on number, duration, and distribution of night-time wake bouts |
| 39879708 | 2025 | Post-hoc RCT analysis | Sleep Medicine | Sleep architecture effects in insomnia with comorbid mild OSA, using zolpidem as reference class comparator |
| 39374004 | 2024 | RCT | JAMA Internal Medicine | Masked-taper behavioral intervention for discontinuing benzodiazepine receptor agonists (incl. zolpidem) |
| 29487083 | 2018 | Review | Pharmacological Reviews | Pharmacology and clinical applications of insomnia drugs beyond benzodiazepines, including Z-drugs |
| 37549414 | 2023 | Review | The Journal of Family Practice | Updated review of insomnia management strategies in primary care |
India Market Information
Zolpidem currently holds no market registrations in India (market_status: Not marketed, total_licenses: 0). No authorization records are available to summarize.
Safety Considerations
Drug Interactions: A total of 274 documented interactions are on record for Zolpidem. Representative examples from the evidence pack:
- Major: Morphine, Morphine (liposomal) — combined use significantly increases risk of CNS/respiratory depression
- Moderate: Bupropion, Aprepitant, Dexamethasone, Cimetidine, Clarithromycin, Dronabinol, Nabilone, Metoclopramide, Miconazole, Clotrimazole, Glycerol phenylbutyrate, Opium, Sibutramine, Troglitazone
- Unknown severity (requires further characterization): Calcitriol, Vitamin A, Phentermine, Pantoprazole
Conclusion and Next Steps
Decision: Hold
Rationale: Efficacy evidence for insomnia is strong and mature (L1, supported by multiple Phase 3 RCTs and network meta-analyses), but a Blocking data gap exists for local safety labeling (warnings/contraindications), which prevents the mandatory S1 safety pre-assessment. Combined with Zolpidem having zero existing India registrations, this represents a new-market-entry decision requiring complete local regulatory review before proceeding.
To proceed, the following is needed:
- Official India-market prescribing information / package insert warnings and contraindications (source: local regulatory authority)
- Confirmed mechanism of action documentation (DrugBank query)
- Structured risk-benefit review of the 274 recorded drug interactions, prioritizing the major-severity opioid interactions (Morphine)
- A defined regulatory pathway for first-time market registration in India, given the current absence of any local license
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.